Testing a 'Scalpel-Like' radiation drug for tough prostate cancers
NCT ID NCT07363486
Summary
This study is testing a new radioactive drug called 225Ac-LNC1011 for men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy. The main goal is to find the safest and most effective dose. Researchers will give the drug to small groups of patients at increasing doses to see how well it works and what side effects it causes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University
RECRUITINGFuzhou, Fujian, 350005, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.